Fingerprint
Dive into the research topics of 'Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: Final analysis of the GAUSS study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically